Jul. 12 at 1:01 PM
$VERU This was posted on endpointsnews
Significantly, dealmaking is holding up, particularly for late-stage drugs that draw interest from the biggest companies in the industry. Both M&A activity and licensing deal values remain strong. Healthcare M&A jumped to 284 deals in the first half of 2025.
Definition of Late-State from Google AI
Late-stage drugs in pharmaceutical development
In the context of drug development, late-stage drugs generally refer to those that have advanced beyond the initial stages of clinical research and are approaching regulatory submission or already undergoing it. This typically encompasses drugs that have completed Phase 2 trials and are currently undergoing Phase 3 trials or have been submitted to regulatory authorities for a new indication.